Here’s Why Chevron (CVX) Stock is an Attractive Pick for Investors

Sorrento’s COVID-19 Cocktail Could Drive Major Upside, Says Analyst

Will a single antibody be enough to stomp out a COVID-19 infection? Sorrento Therapeutics (SRNE) says no. Rather, the company believes that an antibody cocktail could be capable of providing protection against a SARS-CoV-2 coronavirus infection, with the cocktail remaining effective should the virus mutate.To find the select few with the ability to block the S1 protein's interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells, SRNE assessed billions of antibodies. Now, after announcing yet another monoclonal antibody (MaB), STI-4938 (COVIDTRAP), was able to inhibit SARS-CoV-2 viral infection in vitro, some members of the Street think SRNE has what it takes to provide a weapon against the deadly virus.Dawson James analyst Jason Kolbert is standing squarely in the bull camp. He points out that COVIDTRAP, an ACE2-Fc decoy protein, binds firmly to the SARS-CoV-2 virus’ spike protein, with SRNE already getting encouraging feedback from...